Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03735056
Other study ID # 18053
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 30, 2018
Est. completion date October 31, 2020

Study information

Verified date March 2020
Source University of Nottingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PrEliMS study is a mixed-methods feasibility randomised controlled trial of a point of diagnosis intervention programme which aims to provide emotional support for newly diagnosed people with Multiple Sclerosis (MS). This feasibility study will enable us to plan for a definitive trial to evaluate the clinical and cost-effectiveness of this point of diagnosis intervention programme. The aim is to assess the feasibility of the trial procedures and intervention, and to evaluate the key feasibility parameters before proceeding to a definitive trial. Participants (N=60) will be randomised into three groups: (1) usual care; (2) usual care + Support 1 (MS Nurse Support); (2) usual care + Support 2 (MS Nurse Support plus Peer Support).


Description:

Potential participants will be people who have been recently diagnosed with MS (or currently going through diagnosis process), and who are aged 18 years or over, recruited through MS clinics. Participants, after consent, will complete baseline measures before being randomised into to one of three groups: (1) usual care; (2) usual care + Support 1 (MS Nurse Support); (2) usual care + Support 2 (MS Nurse Support plus Peer Support). Group 1 (20 patients) will not receive any intervention. Group 2 (20 patients) will receive Support 1 which will include one face-to-face support session delivered by an MS Nurse. Group 3 (20 patients) will receive Support 2 which includes MS Nurse Support (i.e., Support 1) plus Peer Support. Peer Support will include a minimum of two peer support session delivered by Peer Support Workers (i.e. patients with lived experiences). All groups will receive usual care. The outcome measures will be collected at 3 and 6 months after randomisation by all participants. Feedback interviews with up to 21 participants (7 from each group) and up to 10 service providers (5 MS Nurses who delivered the MS Nurse Support and 5 Peer Support Workers who delivered the Peer Support) will be conducted to assess what parts of the intervention were helpful or unhelpful, the acceptability of randomisation and trial procedures, and the appropriateness of the measures used.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date October 31, 2020
Est. primary completion date October 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients will be eligible to join the trial if they: - are 18 years or over - have recently received a diagnosis of MS (any type of MS) or currently going through MS diagnosis process) - can communicate in English - able and willing to give consent - not receiving psychological intervention Exclusion Criteria: Patients will be excluded if they: - have a severe co-morbid psychiatric condition (e.g. dementia), as reported by patients or their carers or confirmed by the clinical team making the initial approach - are currently receiving psychological interventions or received this within the last three months (we will not exclude those on medication for their mood problems but will record this information). - do not have mental capacity to consent to take part in the trial - are unable to communicate in English

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MS Nurse Support
MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
Peer Support
Peer Support will be delivered by Peer Support Workers using information provision and supportive listening to provide support and advice to patients at diagnosis, and to provide patients the opportunity to talk freely, extensively and confidentially about their experiences, thoughts and feelings about MS diagnosis and its effects on their lives in a non-judgmental and safe environment. Peer Support intervention is person-centred and tailored to the needs and lifestyle of each participant.

Locations

Country Name City State
United Kingdom Nottingham University Hospitals NHS Trust Nottingham

Sponsors (3)

Lead Sponsor Collaborator
University of Nottingham Multiple Sclerosis Society UK, Swansea University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Perceived stress Perceived Stress Scale 4 (PSS4; Cohen, Kamarck, & Mersmelstein, 1983; Cohen & Williamson, 1988) to measure the level of perceived stress among people with MS by assessing their level of perceived uncontrollability and unpredictability on a 5 point scale (0=never, 1=almost never, 2=sometimes, 3=fairly often, 4=very often). The scores for each question are added (after reverse scoring two of the four questions) to give a total score ranging from 0 to 16, with higher scores indicating higher stress. Baseline, 3-month follow-up, and 6-month follow-up
Other Mood Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) will be used to measure the level of mood disturbances. It is a 14-item scale and each item is scored from 0 to 3. The total scores range from 0 to 21 for the anxiety subscale and also for the depression subscale, with higher scores indicating greater levels of anxiety or depression. Baseline, 3-month follow-up, and 6-month follow-up
Other Psychological impact of MS Multiple Sclerosis Impact Scale 29 (MSIS-29) - psychological subscale (Rasch, version 2; Hobart, Lamping, Fitzpatrick, Riazi, & Thompson, 2001; Ramp, Khan, Misajon, & Pallant, 2009) will be used to assess the perceived psychological impact of MS. Psychological subscale has 9 items with 4-point response categories for each item ("not at all", "a little", "moderately", "extremely"). The total score range from 9 to 36, with lower scores indicating little impact of MS and higher scores indicating greater impact. Baseline, 3-month follow-up, and 6-month follow-up
Other Self-efficacy Multiple Sclerosis Self-efficacy Scale (MSSE; Rigby, Domenech, Thornton, Tedman, & Young, 2003) will be used to assess the extent to which participants feel in control of their condition. The scale has 14 items. Each item is presented with a 6-point Likert scale, ranging from "Strongly Disagree" to "Strongly Agree". The scores for each item are added (after reverse scoring six of the 14 items) to give a total score ranging from 14-84, with higher scores indicating an elevated level of self-efficacy. Baseline, 3-month follow-up, and 6-month follow-up
Other Health-related quality of life EQ-5D-5L (Herdman et al., 2011) will be used as a generic patient-reported measure of health-related quality of life and to derive health utilities. Baseline, 3-month follow-up, and 6-month follow-up
Other Service use questionnaire Service use questionnaire was adapted from the service use questionnaire used in the CRAMMS trial (Lincoln et al. 2015). Baseline, 3-month follow-up, and 6-month follow-up
Primary Feasibility of trial procedures [Note: As feasibility studies are used to estimate important parameters to inform the design of a full trial (NIHR, 2018), we outline the key outcomes related to feasibility. These are described below. Please see Outcome 1-15.]
Feasibility of trial procedures will be assessed through feedback interview (qualitative) data from participants and service providers (i.e., questions about the research process/procedures, and suggested changes to the study).
Daily throughout data collection
Primary Acceptability of trial procedures Assessed through feedback interview (qualitative) data from participants and service providers on the trial procedures. Daily throughout data collection
Primary Feasibility of randomisation protocol Assessed through feedback interview (qualitative) data on randomisation protocol and willingness and acceptance of patients to be randomised. Daily throughout data collection
Primary Feasibility of recruitment Number of those eligible who expressed interest/discussed with researcher, number of consenting/randomised patients, reasons for non-participation, retention rates, feedback interview (qualitative) data. Daily throughout data collection
Primary Estimating sample size needed for a Phase III RCT Sample size calculated through effect sizes from ANOVAs, standard deviations and attrition rates. Daily throughout data collection
Primary Appropriateness of measures Completion rates of outcome measures, number of missing online and postal data, estimates of time (minutes) taken to complete measures (from online/phone data or feedback interview data). Daily throughout data collection
Primary Feasibility of self-report data collection Number of missing online and postal data Daily throughout data collection
Primary Feasibility of audio recording support sessions Number of participants consenting to audio recording of sessions and feedback interview data Daily throughout data collection
Primary Acceptability of interventions (Support 1 and Support 2) Drop-out rates (and reasons for withdrawal), number of Support 1 and Support 2 sessions completed, feedback interview data. Daily throughout intervention delivery
Primary Feasibility of delivering Support 1 intervention Number of missed and rescheduled sessions, length of sessions (minutes), operational issues in delivering intervention through feedback interview data. Daily throughout intervention delivery
Primary Feasibility of delivering Support 2 intervention Number of missed and rescheduled sessions, length of sessions (minutes), operational issues in delivering intervention through feedback interview data. Daily throughout intervention delivery
Primary Credibility of interventions Assessed through qualitative feedback interview data (i.e., questions about the content of the intervention, changes experienced). Daily throughout data collection
Primary Fidelity of intervention Fidelity rating on audio data from a sample of support sessions against criteria for PrEliMS model consistency. Daily throughout intervention delivery
Primary Documentation of usual care Data obtained through service use questionnaire and feedback interviews. Daily throughout data collection
Primary Feasibility of collecting data for an economic evaluation using a bespoke service use questionnaire Number of missing or clearly invalid service use questionnaire data, completion rates, exploration of possible ceiling effects, feedback interview (qualitative) data. Daily throughout data collection
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4